Dr. Moskowitz on Important Updates in Hodgkin Lymphoma

Alison J. Moskowitz, MD
Published: Monday, Jan 20, 2020



Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses important updates in Hodgkin lymphoma.

Interim PET scan results have shown prognostic value in patients who have received 2 cycles of chemotherapy, says Moskowitz. As such, multiple studies are investigating the utility of modifying treatment for patients with Hodgkin lymphoma based on interim PET scan results.

Additionally, novel therapies like brentuximab vedotin (Adcetris), as well as nivolumab (Opdivo) and pembrolizumab (Keytruda) have revolutionized the treatment paradigm in the relapsed/refractory setting. Now, these agents are beginning to be evaluated earlier on in treatment to determine their optimal utility, concludes Moskowitz.
SELECTED
LANGUAGE


Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses important updates in Hodgkin lymphoma.

Interim PET scan results have shown prognostic value in patients who have received 2 cycles of chemotherapy, says Moskowitz. As such, multiple studies are investigating the utility of modifying treatment for patients with Hodgkin lymphoma based on interim PET scan results.

Additionally, novel therapies like brentuximab vedotin (Adcetris), as well as nivolumab (Opdivo) and pembrolizumab (Keytruda) have revolutionized the treatment paradigm in the relapsed/refractory setting. Now, these agents are beginning to be evaluated earlier on in treatment to determine their optimal utility, concludes Moskowitz.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x